FBXO7 and colorectal carcinoma: Collectively, our findings suggest that CHEK1 inhibition represents a promising therapeutic strategy for CRC patients harboring FBXO7 defects, and warrants further pre-clinical evaluation, particularly in combination with established chemotherapies.